aBLA Filing Intelligence & Biosimilar Opportunity

Omvoh

Mirikizumab-Mrkz

Antiulcer

IV Infusion

Omvoh is a once-daily oral antibody for adults with moderately to severely active ulcerative colitis. It targets inflammatory pathways to reduce bowel inflammation and improve symptoms.

Approval Date

26-Oct-23

Data Exclusivity Expiry

26-Oct-27

Market Exclusivity Expiry

26-Oct-35

Commercial snapshot

Market performance & projections

Revenue ($M)

265

CAGR (%)

0.3214

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

432

2027

570

2028

697

2029

808

2030

910

2031

1006

2032

1082

Molecule profile

Details & specifications

Molecule

Mirikizumab-Mrkz

Innovator

ELI LILLY

Dosage Form

IV Infusion

Strength

300 mg/15 mL

Therapeutic Category

Antiulcer

Usage

To treat ulcerative colitis

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.